Methods for delivering islet cells and related methods
The method of delivering stem cell-derived cell clusters, particularly SC-islets, addresses the challenge of treating type 1 diabetes by improving glucose tolerance and reducing insulin dependence, without using scaffolds or devices.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- SANA BIOTECHNOLOGY INC
- Filing Date
- 2024-05-21
- Publication Date
- 2026-06-23
AI Technical Summary
The delivery of therapeutically appropriate numbers of stem cell-derived insulin-producing beta cells for treating type 1 diabetes without the use of additional supports such as scaffolds or devices remains challenging.
A method for delivering stem cell-derived cell therapy involves administering a cell suspension of SC-derived cells capable of forming aggregated clusters, with controlled cluster sizes and percentages, either as a dissociated or single-cell suspension, intramuscularly without a biological scaffold.
This approach enables effective delivery of stem cell-derived cells, particularly SC-islets, to treat type 1 diabetes by improving glucose tolerance, reducing insulin dependence, and stabilizing glucose levels, without the need for additional supports.
Smart Images

Figure 2026520439000018 
Figure 2026520439000019 
Figure 2026520439000020